<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911210-0054</DOCNO><DOCID>911210-0054.</DOCID><HL>   Technology Brief -- SmithKline Beecham PLC:   FDA Approves Ulcer Drug   To Prevent Serious Bleeding</HL><DATE>12/10/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   SBE</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><NS>NEW PRODUCTS andamp; SERVICES (PDT)SCIENCE andamp; TECHNOLOGY (SCN)</NS><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>EUROPE (EU)NORTH AMERICA (NME)GREAT BRITAIN (UK)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   SmithKline Beecham PLC said its Tagamet anti-ulcer drugwas approved by the Food and Drug Administration forcontinuous intravenous infusion to prevent uppergastrointestinal bleeding in critically ill patients.   The Anglo-American pharmaceutical company said Tagament isthe first anti-ulcer drug approved to prevent such bleeding.It said critically ill hospitalized patients, for uncertainreasons, are highly vulnerable to potentially fatal uppergastrointestinal bleeding.</LP><TEXT>   Smithkline Beecham said a study found that only 9 of 65patients treated with Tagamet suffered upper gastrointestinalbleeding, compared with 22 of 66 patients treated with aplacebo.</TEXT></DOC>